Li Bohui, Yao Wo, Diao Ran, Yang Boyun, Wang Yongfang, Li Ting, Ge Liuya, Wang Huiying
Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People's Republic of China.
Outpatient Care Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People's Republic of China.
Int Med Case Rep J. 2025 May 28;18:637-644. doi: 10.2147/IMCRJ.S514339. eCollection 2025.
Prurigo nodularis (PN), while rare, presents significant clinical challenges due to its diverse pathogenesis and presentation. Effective therapy recommendations for PN remain limited. Upadacitinib, an oral highly selective type 1 Janus-associated kinase (JAK, Intracellular tyrosine kinases that phosphorylate cytokine receptors). Inhibitor plays an excellent role in alleviating itching in atopic dermatitis (AD). This is a report on the treatment of PN with upadacitinib, which offers a new option for refractory PN.
We share our successful treatment experience of upadacitinib on a 43-year-old female patient with refractory PN failing to conventional therapies. She showed significant improvement at the follow-up visits and no obvious adverse effects happened. We also reviewed published case reports of PN patients and PN-related review researches and made a comprehensive discussion of the potential mechanism of JAK1 inhibitors in treating PN.
Upadacitinib may be a safe and potent alternative for patients with refractory PN.
结节性痒疹（PN）虽罕见，但因其发病机制和表现多样，带来了重大的临床挑战。针对PN的有效治疗建议仍然有限。乌帕替尼是一种口服的高选择性1型 Janus 相关激酶（JAK，磷酸化细胞因子受体的细胞内酪氨酸激酶）抑制剂，在缓解特应性皮炎（AD）瘙痒方面发挥着出色作用。这是一篇关于用乌帕替尼治疗PN的报告，为难治性PN提供了新的选择。
我们分享了乌帕替尼治疗一名43岁难治性PN女性患者的成功经验，该患者对传统疗法无效。随访时她有显著改善，且未发生明显不良反应。我们还回顾了已发表的PN患者病例报告和PN相关综述研究，并对JAK1抑制剂治疗PN的潜在机制进行了全面讨论。
对于难治性PN患者，乌帕替尼可能是一种安全有效的替代药物。
